World-Psoriasis-Day-IFPA-Interview
Interview with the International Federation of Psoriasis Associations (IFPA)
Search
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
trust-through-transparency
Transparency is an essential cornerstone of trust in the healthcare industry
Science & Innovation
Science & Innovation
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
New partnership to develop schizophrenia treatments
Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
Giotrif®
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous hist
Judi – My Asthma Journey
Hayley – My Life With Asthma
Cities join forces for stroke care improvements
Learn how Angels Cities unite to swiftly address stroke symptoms. Quick collaboration saves crucial minutes, minimizing stroke’s devastating effects.
Cardio-Renal-Metabolic Research
Read about our patient-centric approach to cardio-renal-metabolic disease research.
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Grass Roots
Grass Roots Innovation: Championing the Next Generation of Life-Science Innovators
Alesion®
Prophylactic treatment of patients with bronchial asthma. Prophylaxis and symptomatic treatment of allergic rhinitis.
Spiolto® Respimat®
Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Human Health Innovation
Human Health Innovation
Green Chemistry
Green Chemistry is critical for us as it balance the long-term sustainability of business, society, and the environment.
Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
More Health: For People & Animals
More Health: For People & Animals
Fredrik Gruenenfelder
, Lead Risk Management Physician, talks about his career journey, from veterinarian to playing a key role in keeping patients safe.
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia